Vitestro B.V.
Vitestro is a pioneering company in autonomous blood drawing technology, dedicated to transforming patient care and addressing healthcare workforce shortages through innovative robotic solutions. Founded in 2017 and based in Utrecht, Netherlands, Vitestro develops AI-driven, ultrasound-guided blood collection devices that are fully automated, aiming to improve safety, efficiency, and patient experience. The company collaborates with leading hospitals and laboratories across Europe and is on track to obtain CE approval for its devices, with plans for global expansion.
Industries
Nr. of Employees
medium (51-250)
Patents
Contact sensor positioning system, cannula insertion system and method to position a contact sensor
US-12458320-B2
View Details
Contact sensor positioning system, cannula insertion system and method to position a contact sensor
US-12458320-B2
View DetailsProducts
Autonomous robotic phlebotomy device
A clinical device that automates venous blood collection using AI-driven ultrasound imaging for vein localization combined with robotic needle insertion and end-to-end workflow automation from tourniquet application to bandaging.
Autonomous robotic phlebotomy device
A clinical device that automates venous blood collection using AI-driven ultrasound imaging for vein localization combined with robotic needle insertion and end-to-end workflow automation from tourniquet application to bandaging.
Services
Study design, site coordination and execution support for large-scale clinical validation of autonomous blood draw devices (examples include A.D.O.P.T., NCT05878483).
Workflow integration planning, on-site onboarding and operator training program to prepare clinical staff for supervised or autonomous use of the device.
Generation of clinical and performance data to support CE marking and preparation for other regulatory jurisdictions, including documentation and trial evidence alignment with regulatory requirements.
Commercial engagement services including pre-order management, deployment planning with health systems, and international rollout coordination.
Study design, site coordination and execution support for large-scale clinical validation of autonomous blood draw devices (examples include A.D.O.P.T., NCT05878483).
Workflow integration planning, on-site onboarding and operator training program to prepare clinical staff for supervised or autonomous use of the device.
Generation of clinical and performance data to support CE marking and preparation for other regulatory jurisdictions, including documentation and trial evidence alignment with regulatory requirements.
Commercial engagement services including pre-order management, deployment planning with health systems, and international rollout coordination.
Expertise Areas
- Autonomous robotic phlebotomy development
- Medical robotics engineering
- Ultrasound imaging and AI-based image analysis
- Multicenter clinical trial management and validation
Key Technologies
- Ultrasound imaging (Doppler)
- 3D vascular reconstruction
- AI-driven image analysis
- Robotic actuation for needle insertion
News & Updates
Vitestro showcased its autonomous blood drawing device at the WorldLab-EuroMedLab conference in Rome, attracting significant interest and demonstrating its innovative technology to international laboratory professionals.
Odense University Hospital in Denmark plans to deploy three autonomous blood drawing devices from Vitestro, marking the company's first international order and demonstrating global recognition.
Vitestro raised €12 million in Series A funding to accelerate commercialization and expand its market presence in Europe and the U.S.
The company announced it has obtained CE marking, allowing for commercial use of its device across the European Union.
The A.D.O.P.T. trial met all endpoints, with 95% first-stick success and 98% patient acceptance, demonstrating the device's efficacy and safety.
Vitestro achieved CE marking for its autonomous blood drawing device, confirming compliance with European Medical Device Regulation (MDR).
Vitestro showcased its autonomous blood drawing device at the WorldLab-EuroMedLab conference in Rome, attracting significant interest and demonstrating its innovative technology to international laboratory professionals.
Odense University Hospital in Denmark plans to deploy three autonomous blood drawing devices from Vitestro, marking the company's first international order and demonstrating global recognition.
Vitestro raised €12 million in Series A funding to accelerate commercialization and expand its market presence in Europe and the U.S.
The company announced it has obtained CE marking, allowing for commercial use of its device across the European Union.
The A.D.O.P.T. trial met all endpoints, with 95% first-stick success and 98% patient acceptance, demonstrating the device's efficacy and safety.
Vitestro achieved CE marking for its autonomous blood drawing device, confirming compliance with European Medical Device Regulation (MDR).